NEW YORK (TheStreet) -- Sarepta Therapeutics (SRPT) plunged Thursday after the company reported data from its Phase II study of eteplirsen, an experimental drug designed to treat Duchenne muscular dystrophy.
The data from 144 weeks of the study showed a greater decline in walking ability in patients treated with the drug compared to previous updates on the study. Sarepta still plans to file for FDA approval of eteplirsen by the end of the year.
Duchenne muscular dystrophy is a degenerative disease that causes patients to progressively lose muscle function and eventually leads to death.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV